ストックスクリーナーアプリを入手
254.76
2.42%
-6.31
アフターアワーズ：
255.73
0.97
+0.38%
前日終値:
$261.07
開ける：
$259.92
24時間の取引高:
8.21M
Relative Volume:
1.18
時価総額：
$450.11B
収益：
$62.82B
当期純損益:
$3.60B
株価収益率:
125.66
EPS:
2.0274
ネットキャッシュフロー:
$19.98B
1週間 パフォーマンス:
+0.18%
1か月 パフォーマンス:
+12.12%
6か月 パフォーマンス:
+13.77%
1年 パフォーマンス:
+34.59%
1日の値動き範囲:
$253.60
$260.92
1週間の範囲:
$247.56
$261.63
52週間の値動き範囲:
$184.63
$261.63
Abbvie Inc Stock (ABBV) Company Profile
Compare ABBV vs LLY, JNJ, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
254.76 | 444.60B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,200.06 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
259.33 | 611.36B | 96.36B | 21.04B | 17.80B | 8.6488 |
MRK
Merck Co Inc
|
126.78 | 317.37B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
155.49 | 299.04B | 54.66B | 13.58B | 16.05B | 7.0171 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-30 | アップグレード | BofA Securities | Neutral → Buy |
| 2026-04-21 | 開始されました | Canaccord Genuity | Buy |
| 2026-02-25 | 開始されました | RBC Capital Mkts | Outperform |
| 2026-02-20 | 開始されました | Barclays | Overweight |
| 2026-01-08 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | 再開されました | UBS | Neutral |
| 2025-12-10 | アップグレード | HSBC Securities | Hold → Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-11-04 | ダウングレード | DZ Bank | Buy → Hold |
| 2025-10-14 | ダウングレード | Erste Group | Buy → Hold |
| 2025-10-01 | ダウングレード | HSBC Securities | Buy → Hold |
| 2025-09-17 | アップグレード | Berenberg | Hold → Buy |
| 2025-08-12 | 再開されました | Piper Sandler | Overweight |
| 2025-08-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-12-05 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-04 | アップグレード | Argus | Hold → Buy |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-06-05 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-05-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-01-29 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-12-11 | アップグレード | Goldman | Neutral → Buy |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-10-30 | アップグレード | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-09-29 | 開始されました | Raymond James | Outperform |
| 2023-07-25 | 開始されました | William Blair | Mkt Perform |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-04-05 | ダウングレード | Argus | Buy → Hold |
| 2023-03-01 | 開始されました | Guggenheim | Buy |
| 2023-02-22 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | アップグレード | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-11-08 | ダウングレード | Societe Generale | Buy → Hold |
| 2022-08-01 | ダウングレード | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Underperform |
| 2022-05-06 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2022-02-28 | ダウングレード | UBS | Buy → Neutral |
| 2022-02-03 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-03 | 繰り返されました | Barclays | Equal Weight |
| 2022-02-03 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-03 | 繰り返されました | Goldman | Neutral |
| 2022-01-13 | 開始されました | Redburn | Buy |
| 2022-01-12 | 繰り返されました | BMO Capital Markets | Outperform |
| 2021-12-09 | 再開されました | Wells Fargo | Overweight |
| 2021-11-23 | アップグレード | Societe Generale | Hold → Buy |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2020-11-10 | 再開されました | Bernstein | Outperform |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-06-23 | アップグレード | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | アップグレード | Argus | Hold → Buy |
| 2020-05-18 | 再開されました | BofA/Merrill | Neutral |
| 2020-05-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-05-11 | 再開されました | Morgan Stanley | Overweight |
| 2020-04-20 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | ダウングレード | Societe Generale | Buy → Hold |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-06 | 開始されました | Mizuho | Buy |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | 繰り返されました | Cowen | Outperform |
| 2019-09-26 | アップグレード | Citigroup | Neutral → Buy |
| 2019-08-20 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | 開始されました | Goldman | Neutral |
| 2019-04-29 | アップグレード | BMO Capital Markets | Underperform → Market Perform |
すべてを表示
Abbvie Inc (ABBV) 最新ニュース
AbbVie: Apogee Deal Just Widened An Already Dominant Moat - Seeking Alpha
AbbVie Inc. (ABBV) Hits New Milestone with Venetoclax on Chronic Lymphocytic Leukemia (CLL) Treatment - Yahoo Finance
Here's How Much $1000 Invested In AbbVie 5 Years Ago Would Be Worth Today - Benzinga
RBC Capital reiterates Abbvie stock Outperform rating at $260 By Investing.com - Investing.com Canada
Galderma Slumps After FDA Turns Down Botox Rival Relfydess - The Business of Fashion
AbbVie (ABBV) Shares Dip After Six-Day Surge Amid $10.9B Acquisi - GuruFocus
This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy? - The Motley Fool
AbbVie shares fell after six-session winning streak - MSN
AbbVie Inc. stock outperforms competitors despite losses on the day - MarketWatch
Bristol, Merck, AbbVie face House committee probe over China trials - Seeking Alpha
ABBVAbbvie Inc Latest SEC Filings - Finviz
What Sparked the $43B Jump in AbbVie's Market Cap in the Past Week? - TradingView
Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity - Benzinga
Merck, AbbVie probed by US lawmakers over China clinical trials: report - Yahoo! Finance Canada
US lawmakers probe Merck and AbbVie China clinical trials - grafa.com
AbbVie, Genmab Blood-Cancer Drug Has Competitive Profile -- Market Talk - Moomoo
STIFEL FINANCIAL CORP's AbbVie Inc(ABBV) Holding History - GuruFocus
Why is AbbVie stock slipping today? By Investing.com - Investing.com Canada
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Merck, AbbVie investigated over China military hospital drug trials - Yahoo Finance
AbbVie, Merck Investigated by US House Committee Over Clinical Trials in China - marketscreener.com
Exclusive-US House committee opens investigation into Merck, AbbVie China drug trials - Yahoo! Finance Canada
US House committee opens investigation into Merck, AbbVie China drug trials - marketscreener.com
Nxera reaches fourth R&D milestone under AbbVie accord - The Pharma Letter
AbbVie Stock 6-Day Winning Spree: Stock Climbs 17% - Trefis
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases - marketscreener.com
Nxera Pharma Co LtdNxera Pharma To Receive Us$10 Million Milestone Payment From Abbvie Under Collaboration Targeting Neurological Diseases - TradingView
Big Pharma Has a Case of Merger Mania - The Motley Fool
AbbVie Climbs to 52-Week High: Is the Pharma Giant Still Worth Buying? - NAI500
AbbVie (ABBV) Reports Positive Results for Epkinly in Lymphoma T - GuruFocus
AbbVie (ABBV) Reports Positive Phase 3 Trial Results for DLBCL T - GuruFocus
Juvederm Users Say AbbVie Hid Risks Of Filler - Law360
Is AbbVie (ABBV) One of the 10 Best July Dividend Stocks to Buy? - Insider Monkey
AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma - marketscreener.com
AbbVie lymphoma trial cuts progression risk 60% in Phase 3 test - Stock Titan
AbbVie Stock Rockets 17% With 5-Day Winning Streak - Yahoo Finance
AbbVie (ABBV) Stock After 1-Year 41% Rally And Apogee Deal Valuation Check - Yahoo Finance Singapore
What's Going On With AbbVie Stock Monday?AbbVie (NYSE:ABBV) - Benzinga
AbbVie Stock Hits a New 52-Week High. Has It Gotten Too Expensive to Buy? - AOL.com
AbbVie (ABBV) Wins Backing For Two RINVOQ Skin Disease Uses In Europe - Yahoo Finance
AbbVie (ABBV) Moves 4.2% Higher: Will This Strength Last? - Yahoo Finance
Piper Sandler Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $298 - Moomoo
$100M AbbVie payment backs REGENXBIO (RGNX) Phase IIb/III eye gene therapy - Stock Titan
ABBV Gains Traction as CHMP Recommends Upadacitinib for Alopecia Areata - GuruFocus
AbbVie Stock Surges 17%, With A 5-Day Winning Spree - Trefis
AbbVie Receives Positive CHMP Opinion for Upadacitinib for the Treatment of Adults and Adolescents with Severe Alopecia Areata - Investing News Network
AbbVie Receives Positive CHMP Opinion for Upadacitinib for the Treatment of Adults and Adolescents with Non-segmental Vitiligo - Investing News Network
AbbVie gets positive EU opinion for vitiligo treatment By Investing.com - Investing.com Canada
AbbVie’s upadacitinib receives positive EU opinion for alopecia By Investing.com - Investing.com Canada
AbbVie Inc.(NYSE: ABBV) added to Russell 1000 Value Benchmark - marketscreener.com
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata - Yahoo Finance
Abbvie Inc (ABBV) 財務データ
収益
当期純利益
現金流量
EPS
Abbvie Inc (ABBV) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Purdue David Ryan | SVP, Controller |
Mar 04 '26 |
Sale |
233.56 |
5,230 |
1,221,519 |
2,654 |
2.15%
大文字化:
|
ボリューム (24 時間):